Dr Glynne-Jones is a clinical oncologist at Mount Vernon Centre for Cancer Treatment. He has been a member of the NICE colorectal guidelines group and NICE colorectal clinical standards group. He has also been a member of a NICE committee examining Lynch syndrome, which recommended routine mismatch repair testing in the UK.
He was first author and lead for the European Society of Medical Oncology (ESMO) Guidelines for Rectal Cancer (2017) and for Anal Cancer (2014).
Dr Glynne-Jones is Chief Medical Advisor to the national UK charity Bowel Cancer UK, and has a major interest in communications skills and patient choice. He teaches both within the UK and internationally on developing communication skills for doctors.
He is a member of the European Society for Therapeutic Radiology and Oncology (ESTRO) and the European Society of Medical Oncologists (ESMO) and regularly teaches on their international courses in chemoradiation, rectal cancer and colorectal cancer. He is an active member of the European EORTC gastrointestinal cancer group and participates in their trials. He plays an active role in education within the American Society of Clinical Oncology (ASCO). He also plays an active role in the UK NCRI colorectal research group.
His major research interest is in rectal and anal cancer and in phase I, and translational research in chemoradiation. He has more than 180 peer reviewed publications.
Current areas of research include the integration of immune checkpoint inhibitors into chemoradiation schedules in anal cancer and rectal cancer, the investigation of predictive factors for response and resistance to chemoradiation in anal and rectal cancer, DCE-MRI changes, and the optimal timing for surgery after chemoradiation.